TMDX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-10 | 2023 | Waleed Hassanein, M.D. President and Chief Executive Officer | 633,846 | 0 | 2,467,645 | 1,170,000 | 13,650 | 6,758,070 |
| 2024-04-10 | 2023 | Anil Ranganath | 215,385 | 0 | 892,987 | 180,000 | 5,181 | 2,187,342 |
| 2024-04-10 | 2023 | Nick Corcoran | 338,942 | 100,000 | 851,765 | 300,000 | 73,129 | 2,517,432 |
| 2024-04-10 | 2021 | Tamer Khayal, M.D. Chief Commercial Officer | 386,250 | 0 | 0 | 165,122 | 0 | 1,991,552 |
| 2024-04-10 | 2022 | Tamer Khayal, M.D. Chief Commercial Officer | 421,875 | 0 | 0 | 326,903 | 0 | 1,128,565 |
| 2024-04-10 | 2023 | Tamer Khayal, M.D. Chief Commercial Officer | 445,962 | 0 | 864,258 | 450,000 | 4,146 | 2,630,508 |
| 2024-04-10 | 2021 | Stephen Gordon Chief Financial Officer | 370,800 | 0 | 0 | 158,517 | 0 | 1,969,497 |
| 2024-04-10 | 2022 | Stephen Gordon Chief Financial Officer | 417,715 | 0 | 0 | 326,903 | 0 | 1,124,405 |
| 2024-04-10 | 2023 | Stephen Gordon Chief Financial Officer | 445,965 | 0 | 864,258 | 450,000 | 13,650 | 2,640,015 |
| 2024-04-10 | 2021 | Waleed Hassanein, M.D. President and Chief Executive Officer | 535,000 | 0 | 0 | 457,425 | 0 | 7,370,365 |
| 2024-04-10 | 2022 | Waleed Hassanein, M.D. President and Chief Executive Officer | 575,192 | 0 | 0 | 886,770 | 0 | 3,287,862 |
| 2023-04-12 | 2020 | Stephen Gordon Chief Financial Officer | 370,510 | 141,831 | 0 | 0 | 0 | 917,826 |
| 2023-04-12 | 2022 | Waleed Hassanein, M.D. President and Chief Executive Officer | 575,192 | 0 | 0 | 886,770 | 0 | 3,287,862 |
| 2023-04-12 | 2021 | Waleed Hassanein, M.D. President and Chief Executive Officer | 535,000 | 0 | 0 | 457,425 | 0 | 7,370,365 |
| 2023-04-12 | 2020 | Waleed Hassanein, M.D. President and Chief Executive Officer | 533,627 | 406,100 | 0 | 0 | 0 | 2,385,687 |
| 2023-04-12 | 2022 | Stephen Gordon Chief Financial Officer | 417,715 | 0 | 0 | 326,903 | 0 | 1,124,405 |
| 2023-04-12 | 2021 | Stephen Gordon Chief Financial Officer | 370,800 | 0 | 0 | 158,517 | 0 | 1,969,497 |
| 2023-04-12 | 2022 | Tamer Khayal, M.D. Chief Commercial Officer | 421,875 | 0 | 0 | 326,903 | 0 | 1,128,565 |
| 2023-04-12 | 2021 | Tamer Khayal, M.D. Chief Commercial Officer | 386,250 | 0 | 0 | 165,122 | 0 | 1,991,552 |
| 2023-04-12 | 2020 | Tamer Khayal, M.D. Chief Commercial Officer | 385,947 | 147,741 | 0 | 0 | 0 | 939,173 |
| 2023-04-12 | 2022 | Miriam Provost, Ph.D. Vice President of Global Regulatory Affairs | 337,200 | 0 | 0 | 198,730 | 0 | 813,467 |
| 2023-04-12 | 2021 | Miriam Provost, Ph.D. Vice President of Global Regulatory Affairs | 329,600 | 0 | 0 | 109,592 | 0 | 953,542 |
| 2023-04-12 | 2022 | Laura Damme Vice President, Clinical Affairs | 304,519 | 0 | 0 | 187,040 | 0 | 769,096 |
| 2023-04-12 | 2021 | Laura Damme Vice President, Clinical Affairs | 262,500 | 0 | 0 | 74,813 | 0 | 851,663 |
| 2022-04-20 | 2021 | Laura Damme Vice President, Clinical Affairs | 262,500 | 0 | 0 | 74,813 | 0 | 851,663 |
| 2022-04-20 | 2021 | Miriam Provost, Ph.D. Vice President of Global Regulatory Affairs | 329,600 | 0 | 0 | 109,592 | 0 | 953,542 |
| 2022-04-20 | 2019 | Tamer Khayal, M.D. Chief Commercial Officer | 353,769 | 168,750 | 0 | 0 | 0 | 1,051,372 |
| 2022-04-20 | 2021 | Waleed Hassanein, M.D. President and Chief Executive Officer | 535,000 | 0 | 0 | 457,425 | 0 | 7,370,365 |
| 2022-04-20 | 2020 | Tamer Khayal, M.D. Chief Commercial Officer | 385,947 | 147,741 | 0 | 0 | 0 | 939,173 |
| 2022-04-20 | 2020 | Waleed Hassanein, M.D. President and Chief Executive Officer | 533,627 | 406,100 | 0 | 0 | 0 | 2,385,687 |
| 2022-04-20 | 2021 | Tamer Khayal, M.D. Chief Commercial Officer | 386,250 | 0 | 0 | 165,122 | 0 | 1,991,552 |
| 2022-04-20 | 2019 | Stephen Gordon Chief Financial Officer | 329,923 | 162,000 | 0 | 0 | 0 | 491,923 |
| 2022-04-20 | 2020 | Stephen Gordon Chief Financial Officer | 370,510 | 141,831 | 0 | 0 | 0 | 917,826 |
| 2022-04-20 | 2021 | Stephen Gordon Chief Financial Officer | 370,800 | 0 | 0 | 158,517 | 0 | 1,969,497 |
| 2022-04-20 | 2019 | Waleed Hassanein, M.D. President and Chief Executive Officer | 448,615 | 360,200 | 0 | 0 | 0 | 3,159,298 |
| 2021-04-16 | 2019 | Waleed Hassanein, M.D. President and Chief Executive Officer | 448,615 | 360,200 | 0 | 0 | 0 | 3,159,298 |
| 2021-04-16 | 2020 | Waleed Hassanein, M.D. President and Chief Executive Officer | 533,627 | 406,100 | 0 | 0 | 0 | 2,385,687 |
| 2021-04-16 | 2020 | Tamer Khayal, M.D. Chief Commercial Officer | 385,947 | 147,741 | 0 | 0 | 0 | 939,173 |
| 2021-04-16 | 2019 | Tamer Khayal, M.D. Chief Commercial Officer | 353,769 | 168,750 | 0 | 0 | 0 | 1,051,372 |
| 2021-04-16 | 2020 | Stephen Gordon Chief Financial Officer | 370,510 | 141,831 | 0 | 0 | 0 | 917,826 |
| 2021-04-16 | 2019 | Stephen Gordon Chief Financial Officer | 329,923 | 162,000 | 0 | 0 | 0 | 491,923 |
| 2020-04-14 | 2018 | Waleed Hassanein, M.D. President and Chief Executive Officer | 384,000 | 140,000 | 0 | 0 | 0 | 524,000 |
| 2020-04-14 | 2019 | Tamer Khayal, M.D. Chief Commercial Officer | 353,769 | 168,750 | 0 | 0 | 0 | 1,051,372 |
| 2020-04-14 | 2018 | Tamer Khayal, M.D. Chief Commercial Officer | 315,000 | 100,800 | 0 | 0 | 0 | 415,800 |
| 2020-04-14 | 2019 | Stephen Gordon Chief Financial Officer | 329,923 | 162,000 | 0 | 0 | 0 | 491,923 |
| 2020-04-14 | 2018 | Stephen Gordon Chief Financial Officer | 275,000 | 96,250 | 0 | 0 | 0 | 371,250 |
| 2020-04-14 | 2019 | Waleed Hassanein, M.D. President and Chief Executive Officer | 448,615 | 360,200 | 0 | 0 | 0 | 3,159,298 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
